| Dr Sabrina Holdaway, CRNA | |
|
5475 S 500 E, Ogden, UT 84405-6905 | |
| (801) 479-2111 | |
| Not Available |
| Full Name | Dr Sabrina Holdaway |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 4 Years |
| Location | 5475 S 500 E, Ogden, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619551876 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 133717 (Utah) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 133717 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ogden Regional Medical Center | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nph Anesthesia Of Utah Llc | 9537584313 | 96 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
Berthold Technologies proudly announces the recently established co-operation with their new partner Biametrics GmbH.
As autumn approaches and millions of Americans consider taking an H1N1 Swine Flu vaccination, the integrity of all vaccine developers has been called into question by the financial relationship of a leading vaccine advocate and a pharmaceutical manufacturer. Dr. Paul Offit of Children's Hospital of Philadelphia (CHOP), who was interviewed for a Dateline NBC television special, failed to tell millions of viewers that while he was promoting MMR as safe he had also made tens of millions of dollars from selling another vaccine patent to Merck, which is the manufacturer of MMR.
Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.
A study of nearly 1,200 older patients hospitalized for severe sepsis indicate that those who survive are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons.
› Verified 8 days ago
| Entity Name | Rocky Mountain Anesthesiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487683215 PECOS PAC ID: 6305809492 Enrollment ID: O20041109001170 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
Berthold Technologies proudly announces the recently established co-operation with their new partner Biametrics GmbH.
As autumn approaches and millions of Americans consider taking an H1N1 Swine Flu vaccination, the integrity of all vaccine developers has been called into question by the financial relationship of a leading vaccine advocate and a pharmaceutical manufacturer. Dr. Paul Offit of Children's Hospital of Philadelphia (CHOP), who was interviewed for a Dateline NBC television special, failed to tell millions of viewers that while he was promoting MMR as safe he had also made tens of millions of dollars from selling another vaccine patent to Merck, which is the manufacturer of MMR.
Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.
A study of nearly 1,200 older patients hospitalized for severe sepsis indicate that those who survive are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons.
› Verified 8 days ago
| Entity Name | Nph Anesthesia Of Utah Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366077273 PECOS PAC ID: 9537584313 Enrollment ID: O20200811001268 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
Berthold Technologies proudly announces the recently established co-operation with their new partner Biametrics GmbH.
As autumn approaches and millions of Americans consider taking an H1N1 Swine Flu vaccination, the integrity of all vaccine developers has been called into question by the financial relationship of a leading vaccine advocate and a pharmaceutical manufacturer. Dr. Paul Offit of Children's Hospital of Philadelphia (CHOP), who was interviewed for a Dateline NBC television special, failed to tell millions of viewers that while he was promoting MMR as safe he had also made tens of millions of dollars from selling another vaccine patent to Merck, which is the manufacturer of MMR.
Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.
A study of nearly 1,200 older patients hospitalized for severe sepsis indicate that those who survive are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sabrina Holdaway, CRNA 5458 S 925 E, Ogden, UT 84405-7022 Ph: () - | Dr Sabrina Holdaway, CRNA 5475 S 500 E, Ogden, UT 84405-6905 Ph: (801) 479-2111 |
News Archive
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
Berthold Technologies proudly announces the recently established co-operation with their new partner Biametrics GmbH.
As autumn approaches and millions of Americans consider taking an H1N1 Swine Flu vaccination, the integrity of all vaccine developers has been called into question by the financial relationship of a leading vaccine advocate and a pharmaceutical manufacturer. Dr. Paul Offit of Children's Hospital of Philadelphia (CHOP), who was interviewed for a Dateline NBC television special, failed to tell millions of viewers that while he was promoting MMR as safe he had also made tens of millions of dollars from selling another vaccine patent to Merck, which is the manufacturer of MMR.
Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.
A study of nearly 1,200 older patients hospitalized for severe sepsis indicate that those who survive are at higher risk for long-term cognitive impairment and physical limitations than those hospitalized for other reasons.
› Verified 8 days ago